Hispanic Broadcasting

Hispanic Broadcasting Newswire

Comprehensive Real-Time News Feed for Hispanic Broadcasting.

Results 1 - 20 of 359 in Hispanic Broadcasting

  1. FDA approves knockoff of Amgen's Neupogen chemo recovery drugRead the original story w/Photo

    3 hrs ago | Los Angeles Times

    Amgen decided to enter biosimilars several years ago. "It was a natural extension of our biologic capability," said Vice President Richard Markus.


  2. Valeant Pharmaceuticals Remains A Risky BetRead the original story w/Photo

    3 hrs ago | Seeking Alpha

    The all-cash transaction will be funded through bank debt and bonds, increasing Valeant's net leverage ratio to 5.6. With interest rate hike imminent, Valeant's strategy of keeping a high net leverage ratio to fund growth carries significant risk. The last week was an eventful week for Valeant Pharmaceuticals International, Inc. , which was locked in a bitter takeover battle with Botox-maker Allergan Inc. last year.


  3. Amgen's portfolio threatened as FDA paves path for lower-cost drugsRead the original story w/Photo

    7 hrs ago | Pacific Business Times

    Zarxio, the first biopharmaceutical copycat approved in the U.S., will pave the way for lower-cost alternatives to existing treatments. The U.S. Food and Drug Administration today approved its first-ever biosimilar, a drug known as Zarxio that mimics Amgen's chemotherapy drug Neupogen, placing the Thousand Oaks-based biotech giant under peaked pressure to bring new treatments to market.


  4. Select to View Firm Press ReleaseRead the original story

    10 hrs ago | US Food and Drug Administration

    March 6, 2015 - LAKE FOREST, Ill. - Hospira, Inc., has announced a voluntary recall of one lot of Magnesium Sulfate in 5% Dextrose, Inj., USP, 10 mg/mL to the user level due to confirmed customer reports of an incorrect barcode on the primary bag labeling.


  5. Hospira Statement on FDA Approval of the First Biosimilar in the United StatesRead the original story

    12 hrs ago | Freshnews

    Hospira, Inc. , applauds Sandoz and the U.S. Food and Drug Administration on today's FDA approval of the first biosimilar in the United States. This is a watershed moment for improving patient access to safe, effective and more affordable biologic medicines.


  6. Hospira's Magnesium Injection Lot 42-120-JT May Have Barcode for HeparinRead the original story

    20 hrs ago | ASHP

    Hospira Inc. today announced it is recalling lot 42-120-JT of magnesium sulfate in 5% dextrose injection because the barcode on the bags may actually be the machine-readable code for 1000-mL bags of heparin sodium 2 units/mL. The company said the barcode on the magnesium bags' overwrap is correct.


  7. Hospira Issues A Voluntary Nationwide Recall of One Lot of 0.9%...Read the original story

    Yesterday | US Food and Drug Administration

    FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.


  8. Why I Believe Pfenex Is A Strong BuyRead the original story w/Photo

    Saturday Feb 28 | Seeking Alpha

    A recent new deal with Hospira could add $51 million upfront, $291 million in sales-based milestones and tiered double-digit royalty giving Pfenex $100 million in cash by midyear. This is a brief article why I believe Pfenex Inc. is a compelling situation to own for the long term.


  9. Hospira launches first biosimilar monoclonal antibody (mAb) Inflectra (infliximab) in the UKRead the original story

    Friday Feb 27 | Medical News Today

    Hospira, Inc., a world leader in the development of biosimilar therapies, recently announced the UK launch of the first biosimilar monoclonal antibody , Inflectra . Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis , psoriatic arthritis , ankylosing spondylitis , adult and paediatric Crohn's disease , adult and paediatric ulcerative colitis and plaque psoriasis .


  10. Akorn Stock Goes Nuts As Buyout Strategy Pays OffRead the original story w/Photo

    Thursday Feb 26 | Investor's Business Daily

    Akorn's earnings excluding one-time items jumped 257% from a year earlier to 50 cents a share in Q4, topping analysts' consensus by 5 cents, according to Thomson Reuters. Sales climbed 168% to $227.8 million, about $10 million above the Street's average prediction.


  11. Short Interest Falls 63.7% For HospiraRead the original story w/Photo

    Thursday Feb 26 | Forbes.com

    The most recent short interest data has been released by the NASDAQ for the 02/13/2015 settlement date, which shows a 3,335,142 share decrease in total Inc , to 1,903,684, a decrease of 63.66% since 01/30/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.


  12. Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UKRead the original story w/Photo

    Thursday Feb 26 | Medical News

    Patients in the UK can finally benefit from the availability of Inflectra following the patent expiry of reference product Remicade Inflectra provides an alternative, potentially more affordable treatment option for people suffering from severe, debilitating diseases such as rheumatoid arthritis and inflammatory bowel disease while maintaining comparable quality, efficacy and safety to the reference product As a result of competition, the large savings expected to be generated with biosimilars can provide an opportunity to improve patient access to life-changing medications. Hospira, Inc. , a world leader in the development of biosimilar therapies, recently announced the UK launch of the first biosimilar monoclonal antibody , Inflectra .


  13. Warehouse SupervisorRead the original story

    Wednesday Feb 25 | Monster.com

    Thank you for your interest in the Warehouse Supervisor . To begin the application process, please enter your information below.


  14. Biosimilar copies of blockbuster drug launch in major EU marketsRead the original story

    Wednesday Feb 25 | Vallejo News

    Cheap versions of a top-selling drug for rheumatoid arthritis and Crohn's disease are being launched across major European markets in an important advance for a new type of medicines known as biosimilars. The products from South Korean firm Celltrion and its partners Hospira and Mundipharma will compete with Remicade, the original branded drug from Johnson & Johnson and Merck & Co .


  15. Cubist Pharms., Inc. v. Hospira, Inc.Read the original story w/Photo

    Tuesday Feb 24 | JD Supra

    Case Name: Cubist Pharms., Inc. v. Hospira, Inc. , No. 12-367-GMS, 2014 U.S. Dist.


  16. 8 stocks driving the epic market rallyRead the original story w/Photo

    Friday Feb 20 | USA Today

    It's been an epic month for stocks. The Standard & Poor's 500 is having its best month since October 2011.


  17. Drug Roundup: February 20, 2015Read the original story

    Friday Feb 20 | Value Line

    There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Pfizer Inc. , Hospira Inc. , Valeant Pharmaceuticals , Salix Pharmaceuticals , Actavis plc , and Allergan Inc. .


  18. Hospira's Q4 Earnings Were Bright, Though Acquisition Is In The CardsRead the original story w/Photo

    Thursday Feb 19 | GuruFocus.com

    Lake Forest-based injectables company Hospira reported its fourth-quarter earnings on February 12, and the number mix added delight to its investors and skeptical analysts since it crossed the Street expectations. In fact, the results were declared just a week after the company agreed to the proposal of being acquired by pharma giant Pfizer for a whopping sum of $16 billion.


  19. Hospira, Inc. Shareholder Alert: Rigrodsky & Long, P.a. Announces Investigation Of BuyoutRead the original story

    Wednesday Feb 18 | Business Wire

    Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Hospira, Inc. regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by Pfizer Inc. , in a transaction valued at approximately $17 billion. Under the terms of the agreement, public shareholders of Hospira would receive $90.00 in cash for each share of Hospira they own.


  20. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Tuesday Feb 17 | Business Wire

    Copal Amba A un importante fo... )--StitcherAds, provider innovativo di tecnologia promozionale, ha annunciato oggi di essere entrata a far parte del programma di marketing per partner di Face... )--AHF: L.A. County Finally Acknowledges Meningitis Threat-2 Years Late; County health officials are currently surveying medical providers asking if they knew the DPH rec... )--Heron Resources Limited is pleased to report a significant intercept of high-grade massive sulphide grading approximately 18% Zn from the discove... SABA SOFTWARE, INC. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Saba Software, Inc. Over the Proposed Sale of the Company to Vector Capital )--SABA SOFTWARE, INC.